Quanterix Corp (NASDAQ: QTRX)

Quanterix Corporation is a life sciences company focused on accelerating biomarker breakthroughs from discovery to diagnostics through its ultrasensitive detection platforms. The company’s core Simoa technology enables detection of protein biomarkers at femtomolar concentrations in blood serum and other fluids, far surpassing the sensitivity of conventional immunoassays. Complementing this, Quanterix Spatial Biology solutions allow multiplexed protein analysis at single cell resolution within intact tissue sections, preserving spatial context and cellular architecture. Together these platforms support research in neurology, oncology, immunology and inflammation and have been cited in over six thousand scientific publications. As of the end of 2025 Quanterix reported an installed base of more than two thousand five hundred instruments worldwide, reflecting broad adoption among academic research labs contract research organizations and biopharmaceutical firms. The company continues to invest in next generation instrument development and assay menu expansion to address emerging diagnostic opportunities.

Quanterix generates revenue from three principal streams. First, the sale of its Simoa and Spatial Biology instruments, including the HD-X SR-X SP-X PhenoCycler and PhenoImager platforms, contributes upfront capital receipts. Second, recurring revenue comes from the sale of assay kits, consumables, and reagents that customers use to run tests on those instruments, covering neurology, oncology, immunology, and inflammation biomarker panels. Third, the company provides contract research services and clinical laboratory testing through its CLIA certified Accelerator Laboratory, offering LDTs such as LucentAD Complete, Simoa NfL, and p Tau assays, as well as extended warranty and service contracts on its installed base of equipment. Additionally, Quanterix earns income from licensing its proprietary bead based and planar array technologies to third parties and from collaborative development agreements with pharmaceutical partners. This diversified revenue model supports steady cash flow while enabling reinvestment in research development and commercial expansion.

Quanterix occupies a leading niche in the ultrasensitive biomarker detection market, competing with established players such as Bio Techne, MesoScale Discovery, 10x Genomics, Vizgen, Bruker, Miltenyi Biotec, and Standard BioTools. The company’s competitive advantages stem from its femtomolar sensitivity, multiplexing capabilities, and proprietary Simoa bead based and planar array technologies that enable detection of low abundance proteins invisible to conventional assays. Its Spatial Biology platforms further differentiate the offering by delivering single cell protein mapping within intact tissue, a capability not widely available among rivals. Quanterix also benefits from a strong intellectual property portfolio, a growing installed base of over two thousand five hundred instruments, and a reputation for data accuracy and reproducibility that has been validated in thousands of peer reviewed publications. These factors together support its positioning as a trusted partner for academic research, contract research organizations, and biopharmaceutical companies seeking innovative biomarker solutions.

Quanterix serves a diverse customer base that includes research laboratories, contract research organizations, academic institutions, and biopharmaceutical companies engaged in drug discovery and development. The company also provides clinical laboratory testing services to hospital networks and reference labs, with partnerships covering more than twenty five major healthcare institutions across the United States and Europe as of the end of 2025. Through its Accelerator Laboratory, Quanterix offers LDTs such as LucentAD Complete and Simoa NfL to neurologists, oncologists, and immunologists seeking noninvasive diagnostic information. Additionally, the subsidiary UmanDiagnostics supplies NfL antibodies and ELISA kits to distributors and end users worldwide, further broadening the reach of its biomarker technologies. This mix of research focused and clinical oriented customers supports both upstream biomarker discovery and downstream diagnostic adoption.